Published in Br J Cancer on August 01, 2003
FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging (2010) 7.82
Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol (2014) 6.10
FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging (2014) 2.79
Quantification of FDG PET studies using standardised uptake values in multi-centre trials: effects of image reconstruction, resolution and ROI definition parameters. Eur J Nucl Med Mol Imaging (2006) 2.08
Positron Emission Tomography (PET) radiotracers in oncology--utility of 18F-Fluoro-deoxy-glucose (FDG)-PET in the management of patients with non-small-cell lung cancer (NSCLC). J Exp Clin Cancer Res (2008) 0.90
Early evaluation of the effects of chemotherapy with longitudinal FDG small-animal PET in human testicular cancer xenografts: early flare response does not reflect refractory disease. Eur J Nucl Med Mol Imaging (2008) 0.84
Prognostic value of volumetric parameters measured by 18F-FDG PET/CT in patients with head and neck squamous cell carcinoma. Eur J Nucl Med Mol Imaging (2013) 0.83
Early prediction of survival following induction chemotherapy with DCF (docetaxel, cisplatin, 5-fluorouracil) using FDG PET/CT imaging in patients with locally advanced head and neck squamous cell carcinoma. Eur J Nucl Med Mol Imaging (2012) 0.79
αvβ3 imaging can accurately distinguish between mature teratoma and necrosis in 18F-FDG-negative residual masses after treatment of non-seminomatous testicular cancer: a preclinical study. Eur J Nucl Med Mol Imaging (2010) 0.78
Quantitative Assessment of Radionuclide Uptake and Positron Emission Tomography-computed Tomography Image Contrast. World J Nucl Med (2016) 0.75
SOR: project methodology. Br J Cancer (2001) 5.24
FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, "Onko-PET III", 21 July and 19 September 2000. Eur J Nucl Med (2001) 1.36
Positron emission tomography: establishing priorities for health technology assessment. Health Technol Assess (1999) 1.06
Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab (2006) 5.78
Transferable enzymatic resistance to third-generation cephalosporins during nosocomial outbreak of multiresistant Klebsiella pneumoniae. Lancet (1987) 5.45
SOR: project methodology. Br J Cancer (2001) 5.24
Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst (1995) 3.00
Microcarcinoma of the thyroid gland: the Gustave-Roussy Institute experience. Cancer (1998) 2.57
Intestinal decontamination for control of nosocomial multiresistant gram-negative bacilli. Study of an outbreak in an intensive care unit. Ann Intern Med (1989) 2.16
Idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma: results of the IDASPHERE phase I trial. Aliment Pharmacol Ther (2014) 2.11
Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'étude des tumeurs à calcitonine. Clin Endocrinol (Oxf) (1998) 1.99
Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab (2005) 1.98
Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients. J Clin Endocrinol Metab (2007) 1.87
Localization of a susceptibility gene for familial nonmedullary thyroid carcinoma to chromosome 2q21. Am J Hum Genet (2001) 1.68
Brief report: heavy-chain deposition disease. N Engl J Med (1993) 1.63
Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med (1996) 1.49
["Standards, Options and Recommendations 2001" for radiotherapy in patients with non-metastatic infiltrating breast cancer. Update. National Federation of Cancer Campaign Centers (FNCLCC)]. Cancer Radiother (2002) 1.39
[Association of celiac disease and antiphospholipid syndrome]. Presse Med (1998) 1.39
[Sentinel lymph node biopsy in breast cancer: feasibility study and initial experiments]. Gynecol Obstet Fertil (2002) 1.38
In vivo and in vitro invasiveness of a rat colon-cancer cell line maintaining E-cadherin expression: an enhancing role of tumor-associated myofibroblasts. Int J Cancer (1994) 1.33
Screening for multiple endocrine neoplasia type 2a with DNA-polymorphism analysis. N Engl J Med (1989) 1.32
Tomoscintigraphy for detecting gastrointestinal and medullary thyroid cancers: first clinical results using radiolabelled monoclonal antibodies against carcinoembryonic antigen. Br Med J (Clin Res Ed) (1982) 1.25
HSP27 as a mediator of confluence-dependent resistance to cell death induced by anticancer drugs. Cancer Res (1997) 1.22
Increase of CD4+ CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+ CD25+ T lymphocytes. Clin Exp Immunol (2007) 1.20
Risk and penetrance of primary hyperparathyroidism in multiple endocrine neoplasia type 2A families with mutations at codon 634 of the RET proto-oncogene. Groupe D'etude des Tumeurs à Calcitonine. J Clin Endocrinol Metab (1998) 1.18
Tumor localization in patients by radiolabeled monoclonal antibodies against colon carcinoma. Cancer Res (1983) 1.16
Prevalence and parental origin of de novo RET mutations in multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma. Le Groupe d'Etude des Tumeurs a Calcitonine. Am J Hum Genet (1997) 1.16
[Good clinical practice in nutritional management in cancer patients: malnutrition and nutritional assessment]. Bull Cancer (1999) 1.13
Early detection of recurrence by 18FDG-PET in the follow-up of patients with colorectal cancer. Br J Cancer (2008) 1.08
[Standards, options and recommendations: nutritional support in palliative or terminal care of adult patients with progressive cancer]. Bull Cancer (2001) 1.07
Sick leave for follow-up control in thyroid cancer patients: comparison between stimulation with Thyrogen and thyroid hormone withdrawal. Eur J Endocrinol (2007) 1.06
Dual-isotope myocardial imaging: feasibility, advantages and limitations. Preliminary report on 231 consecutive patients. Eur J Nucl Med (1994) 1.06
Assessment of the incremental value of recombinant thyrotropin stimulation before 2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancer. J Clin Endocrinol Metab (2009) 1.04
Cancer cell sensitization to fas-mediated apoptosis by sodium butyrate. Cell Death Differ (1998) 1.02
[Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study]. Rev Neurol (Paris) (2008) 1.01
Inconstant association between 27-kDa heat-shock protein (Hsp27) content and doxorubicin resistance in human colon cancer cells. The doxorubicin-protecting effect of Hsp27. Eur J Biochem (1996) 0.98
Central nervous system involvement in Sjögren's syndrome: evidence from neuropsychological testing and HMPAO-SPECT. Ann Med Interne (Paris) (1999) 0.98
Immunoscintigraphy of human lung squamous cell carcinoma using an iodine-131 labelled monoclonal antibody (Po66). Br J Cancer (1990) 0.97
Biodistribution study of 99mTc-labeled LDL in B16-melanoma-bearing mice. Visualization of a preferential uptake by the tumor. Int J Cancer (1993) 0.97
Identification of tumor-infiltrating macrophages as the killers of tumor cells after immunization in a rat model system. J Immunol (2001) 0.97
Validity of the polar S810 to measure R-R intervals in children. Int J Sports Med (2007) 0.96
Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal. J Clin Endocrinol Metab (2009) 0.96
Inapparent polycythemia vera: an unrecognized diagnosis. Am J Med (1997) 0.96
Improvement of the Cockcroft-Gault equation for predicting glomerular filtration in cancer patients. Bull Cancer (1998) 0.95
Chemotherapy overcomes TRAIL-R4-mediated TRAIL resistance at the DISC level. Cell Death Differ (2010) 0.95
Concurrent lymphoma and metastatic breast carcinoma in the axillary, confounding sentinel lymph-node biopsy. Eur J Surg Oncol (2004) 0.94
Teratogenic effect of an inhibitor of cholesterol synthesis (AY 9944) in rats: correlation with maternal cholesterolemia. J Nutr (1980) 0.94
[Review of the literature, search of reports and critical reading of articles in cancerology]. Bull Cancer (1998) 0.94
False aneurysm of the internal carotid artery in Behçet's disease: successful combined endovascular treatment with stent and coils. Rheumatology (Oxford) (1999) 0.93
Suceptibility of aminoglycoside-resistant gram-negative bacilli to amikacin: delineation of individual resistance patterns. J Infect Dis (1976) 0.93
Amiodarone-induced enhancement of doxorubicin and 4'-deoxydoxorubicin cytotoxicity to rat colon cancer cells in vitro and in vivo. Cancer Res (1986) 0.93
Mechanisms of resistance of confluent human and rat colon cancer cells to anthracyclines: alteration of drug passive diffusion. Cancer Res (1990) 0.92
CT and (18)F-deoxyglucose (FDG) image fusion for optimization of conformal radiotherapy of lung cancers. Int J Radiat Oncol Biol Phys (2001) 0.92
Evaluation of FDG uptake by renal malignancies (primary tumor or metastases) using a coincidence detection gamma camera. J Nucl Med (2000) 0.91
Fluorocholine (18F) and sodium fluoride (18F) PET/CT in the detection of prostate cancer: prospective comparison of diagnostic performance determined by masked reading. Q J Nucl Med Mol Imaging (2011) 0.90
[Standards, Options and Recommendations (SOR) for tumor markers in breast cancer. SOR Working Group]. Bull Cancer (2000) 0.89
Epinephrine enhances penetration and anti-cancer activity of local cisplatin on rat sub-cutaneous and peritoneal tumors. Int J Cancer (1999) 0.89
Calcitonin treatment of post-menopausal osteoporosis. Evaluation of efficacy by principal components analysis. Biomedicine (1975) 0.89
Short- and long-term somatostatin analogue treatment in patients with hypoglycaemia related to endogenous hyperinsulinism. Clin Endocrinol (Oxf) (2007) 0.88
Clinical pharmacokinetics of alpha 1-antitrypsin in homozygous PiZ deficient patients. Clin Pharmacokinet (1992) 0.88
Confluence-dependent resistance in human colon cancer cells: role of reduced drug accumulation and low intrinsic chemosensitivity of resting cells. Int J Cancer (1992) 0.88
Metastatic neuroblastoma in children older than one year: prognostic significance of the initial metaiodobenzylguanidine scan and proposal for a scoring system. Cancer (1996) 0.87
[Standards, Options and Recommendations (SOR) for the use of appetite stimulants in oncology. Work group. Federation of the French Cancer Centres (FNCLCC)]. Bull Cancer (2000) 0.87
Comparison of the kinetics of active efflux of 99mTc-MIBI in cells with P-glycoprotein-mediated and multidrug-resistance protein-associated multidrug-resistance phenotypes. Eur J Biochem (1998) 0.87
Early and delayed SPECT using N-isopropyl p-iodoamphetamine iodine 123 in cerebral ischemia. A prognostic index for clinical recovery. Arch Neurol (1987) 0.87
Radioiodinated meta-iodobenzylguanidine uptake in medullary thyroid cancer. A French cooperative study. Cancer (1987) 0.87
Circumvention of confluence-dependent resistance in a human multi-drug-resistant colon-cancer cell line. Int J Cancer (1995) 0.87
Cytofluorescence localization of adriamycin in resistant colon cancer cells. Cancer Chemother Pharmacol (1984) 0.86
[The effect of intra-abdominal temperature on the tissue and tumor diffusion of intraperitoneal cisplatin in a model of peritoneal carcinomatosis in rats]. Chirurgie (1999) 0.86
[Locally advanced unresectable pancreatic cancer: Induction chemoradiotherapy followed by maintenance gemcitabine versus gemcitabine alone: Definitive results of the 2000-2001 FFCD/SFRO phase III trial]. Cancer Radiother (2011) 0.86
[(18)F]FDG in childhood lymphoma: clinical utility and impact on management. Eur J Nucl Med Mol Imaging (2002) 0.85
Clinical significance of a low concentration of thyrotropin: five immunometric "kit" assays compared. Clin Chem (1987) 0.85
Effect of training and detraining on heart rate variability in healthy young men. Int J Sports Med (2007) 0.85
Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab. Ann Oncol (2011) 0.85
Thyroglobulin measurement and postablative iodine-131 total body scan after total thyroidectomy for differentiated thyroid carcinoma in patients with no evidence of disease. Eur J Cancer (1996) 0.85
Isolated metastatic adrenal involvement with colon cancer and FDG coincidence detection imaging. Clin Nucl Med (2003) 0.85
Calcitonin precursor levels in human medullary thyroid carcinoma. Thyroid (2003) 0.85
Biodistribution, dosimetry, and clinical evaluation of technetium-99m ethyl cysteinate dimer in normal subjects and in patients with chronic cerebral infarction. J Nucl Med (1989) 0.85
Fluorodeoxyglucose positron emission tomography fails to detect distant metastases at initial staging of melanoma patients with metastatic involvement of sentinel lymph node. Br J Dermatol (2011) 0.84
[Cavernous hemangioma of the liver associated with angiosarcoma: malignant transformation?]. Gastroenterol Clin Biol (1991) 0.84
[Pulmonary malignant melanoma: primary or metastatic?]. Rev Mal Respir (2009) 0.84
Diagnosis of osteomyelitis in the diabetic foot with a 99mTc-HMPAO leucocyte scintigraphy combined with a 99mTc-MDP bone scintigraphy. Diabetes Metab (2002) 0.84
Cytotoxic effects of acoustic cavitation on HT-29 cells and a rat peritoneal carcinomatosis in vitro. Cancer Res (1991) 0.84
Osteoradionecrosis of the hyoid bone: a report of 3 cases. Am J Otolaryngol (2000) 0.84
6-[F-18]fluoro-L-DOPA positron emission tomography in the imaging of Merkel cell carcinoma: preliminary report of three cases with 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography or pentetreotide-(111In) SPECT data. Mol Imaging Biol (2006) 0.83
The retrospective binning method improves the consistency of phase binning in respiratory-gated PET/CT. Phys Med Biol (2012) 0.83
Pre-clinical study of the epinephrine-cisplatin association for the treatment of intraperitoneal carcinomatosis. Eur J Surg Oncol (2001) 0.83
Granulocyte-macrophage colony-stimulating factor alone or with dacarbazine in metastatic melanoma: a randomized phase II trial. Br J Cancer (2001) 0.83
Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in elderly patients. Clin Pharmacokinet (1990) 0.83
Pharmacokinetics of intravenously administered 125I-labelled human alpha 1-acid glycoprotein. Clin Pharmacokinet (1986) 0.83
[Standards, Options and Recommendations for home parenteral or enteral nutrition in adult cancer patients]. Bull Cancer (2001) 0.83
[18-FDG positon emission tomography and distal metastasis from lung cancer]. Rev Pneumol Clin (2005) 0.83
What is currently the best radiopharmaceutical for the hybrid PET/CT detection of recurrent medullary thyroid carcinoma? Curr Radiopharm (2013) 0.82
Evidence for a discrete UTP receptor in cardiac endothelial cells. Br J Pharmacol (1996) 0.82
New insights into the kinetic resistance to anticancer agents. Cytotechnology (1998) 0.82
Contribution of the cyclin-dependent kinase inhibitor p27KIP1 to the confluence-dependent resistance of HT29 human colon carcinoma cells. Int J Cancer (1998) 0.82
Impact of [18F]-fluorodeoxyglucose ([18F]-FDG) imaging in sarcoidosis: unsuspected neurosarcoidosis discovered by [18F]-FDG PET and early metabolic response to corticosteroid therapy. Br J Radiol (2007) 0.82